MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.10
-0.11
-2.11%
After Hours: 5.10 0 0.00% 16:00 09/23 EDT
OPEN
5.19
PREV CLOSE
5.21
HIGH
5.19
LOW
5.02
VOLUME
106.00K
TURNOVER
--
52 WEEK HIGH
10.98
52 WEEK LOW
4.460
MARKET CAP
255.73M
P/E (TTM)
-4.0970
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Reflecting on ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns Over The Last Five Years
We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...
Simply Wall St. · 1d ago
ProQR to Participate in Upcoming Investor Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for inherited retinal diseases (IRDs), today announced that Company management
GlobeNewswire · 09/03 12:00
Jounce Therapeutics rallies on license deal with Gilead, Tracon Pharma follows, I-Mab, Kindred Biosciences among major losers
Gainers: Jounce Therapeutics (JNCE) +42%, TRACON Pharmaceuticals (TCON) +13.8%, Nano-X Imaging (NNOX) +13.6%, Athenex (ATNX) +11.5%, Surface Oncology (SURF) +8%.Losers: I-Mab (IMAB) -14.5%, Kindred Biosciences (KIN) -13.7%, ProQR Therapeutics (PRQR) -13%, Vaxart (VXRT) -12.9%, ADiTx Therapeutics (ADTX) -12.2%.
Seekingalpha · 09/01 14:57
ProQR Therapeutics: Bringing A New Cure To The Market
Covid-19 is delaying ProQR’s pivotal trial, leading to share price fall.There is uncertainty around when the trial will be finished, which can potentially delay the revenue into 2023.The company is sufficiently funded into H2 2022 and their drug pipeline looks positive.
Seekingalpha · 08/31 18:30
ProQR reports Q2 results
ProQR (NASDAQ:PRQR): Q2 GAAP EPS of -€0.08. Other income of €8.67M (+1448.2% Y/Y). Cash and equivalents of €87.1M. Press Release
seekingalpha · 08/07 02:25
ProQR Announces Second Quarter 2020 Operating and Financial Results
* Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial; * Strategic convertible debt financing extends runway into 2023 if ful
GlobeNewswire · 08/06 20:30
ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.
GlobeNewswire · 07/21 11:00
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
Benzinga · 07/15 11:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRQR. Analyze the recent business situations of ProQR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRQR stock price target is 25.94 with a high estimate of 39.65 and a low estimate of 19.82.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 32.77M
% Owned: 65.35%
Shares Outstanding: 50.14M
TypeInstitutionsShares
Increased
17
860.96K
New
12
-357.62K
Decreased
13
731.30K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.26%
Pharmaceuticals & Medical Research
-1.30%
Key Executives
Chairman - Supervisory/Independent Director
Dinko Valerio
Chairman - Management/Chief Executive Officer
Daniel De Boer
Independent Director/Supervisory Board
Bart Filius
Vice President/Director of Investor Relations/IR Contact Officer
Lisa Hayes
Independent Director/Supervisory Board
Theresa Heggie
Independent Director/Supervisory Board
Alison Lawton
Independent Director/Supervisory Board
Antoine Papiernik
Independent Director/Supervisory Board
James Shannon
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PRQR
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRQR stock methods without spending real money on the virtual paper trading platform.